ArticleHerz2026
Relationship between HAVOC score and new-onset atrial fibrillation in patients with ST elevation myocardial infarction.
Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is a common electrical complication in patients with acute myocardial infarction. The HAVOC score was originally proposed as a clinical tool for predicting AF in patients with cryptogenic stroke or transient ischemic attack. This study evaluated the predictive value of the HAVOC score for new-onset AF (NOAF) in patients with ST-segment elevation myocardial infarction (STEMI).
methodBetween August 2019 and December 2024, the data of 1640 patients (mean age: 56.3 ± 11.2 years, male: 1134, 69.1%) with STEMI were retrospectively analyzed. Patients were divided into two groups: those with and those without NOAF. All patients underwent electrocardiographic monitoring and echocardiographic evaluation following primary percutaneous coronary intervention.
resultsOverall, NOAF was observed in 115 patients. A comparison of the clinical and demographic characteristics between the groups showed that age, hypertension frequency, chronic obstructive pulmonary disease, and history of stroke were higher in the NOAF group. Left ventricular ejection fraction was significantly lower (38.2 ± 10.8 vs. 47.9 ± 10.1%, p < 0.001) and left atrial diameter (42.2 ± 4.5 vs. 37.5 ± 4.1 mm, p = 0.001) was significantly higher in these patients. Furthermore, the incidence of unsuccessful intervention, contrast-induced nephropathy, and in-hospital mortality as well as the HAVOC score were significantly higher in patients with NOAF. A high HAVOC score (odds ratio [OR] = 1.078; 95% confidence interval [CI]: 1.022-1.258; p = 0.001) was identified as an independent predictor of NOAF in patients with STEMI.
conclusionThe HAVOC score appears to be a useful tool for predicting NOAF in patients with STEMI. Identifying individuals with high HAVOC scores may enable early recognition and prevention of AF-related complications.
Indexed as
Identifiers
42240851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.